查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1608217

腸漏症候群治療市場：按治療類型、給藥途徑、分銷管道和最終用戶分類 - 全球預測 2025-2030

Lennox-Gastaut Syndrome Treatment Market by Therapy Type (Non-Surgical Treatment, Surgery), Route of Administration (Oral, Parenteral), Distribution Channel, End Users - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

腸漏症候群治療市場2023年估值為6.4329億美元，預計到2024年將達到6.7063億美元，複合年成長率為5.28%，到2030年將達到9.2238億美元。

腸漏症候群(LGS) 是一種罕見且嚴重的癲癇類型，通常始於兒童早期，以多種癲癇類型和認知功能障礙為特徵。 LGS 治療的市場範圍包括診斷、癲癇發作管理和改善患者生活品質。目前，考慮到 LGS 的嚴重程度和抗治療性，市場受到高度未滿足的醫療需求的推動。用途包括抗癲癇藥物、飲食療法和手術干預，重點是減少癲癇發作頻率和嚴重程度。最終使用領域主要包括兒科神經科、專科診所、醫院和居家照護環境。

主要市場統計
基準年[2023] 64329萬美元
預測年份 [2024] 67063萬美元
預測年份 [2030] 92238萬美元
複合年成長率（%） 5.28%

LGS 治療市場的成長很大程度上取決於意識和診斷能力的提高，從而實現早期檢測。此外，正在進行的臨床試驗和對大麻二酚（CBD）製劑等新藥物機制的研究為市場擴張提供了潛在的機會。研究還包括利用基因研究和個人化醫療的進步來開發更有針對性的治療方法。然而，市場面臨治療成本高、現有藥物副作用以及新藥認證複雜的監管環境等限制，為成長帶來挑戰。此外，我們對 LGS 潛在病理生理學的了解有限，為突破性創新創造了充滿挑戰的環境。

創新和研究的最佳潛在領域包括尋找具有改善功效和安全性的新型藥物製劑、增強神經刺激設備等非藥物療法，例子包括基因治療的進展。鼓勵合作研究工作以及與學術機構的夥伴關係也可以為開創性治療鋪平道路。市場的動態和利基性質要求同時關注治療方法開發和綜合護理模式。產業公司應投資於長期研發和策略合作夥伴關係，以創建創新的解決方案，解決與 LGS 相關的癲癇和認知障礙。

市場動態：快速發展的腸漏症候群治療市場的關鍵市場洞察

腸漏症候群治療市場正因供需的動態交互作用而轉變。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助消費行為及其對製造業的影響。

  • 市場促進因素
    • 具有 LGS 危險因子並需要治療的人口不斷增加
    • 各國政府和國際組織對 LGS 的認可度不斷提高
    • 孤兒藥認定增加
  • 市場限制因素
    • LGS 診斷的限制和治療費用高
  • 市場機會
    • LGS 處理植物化學簡介
    • LGS治療的技術進步
  • 市場挑戰
    • 與現有治療相關的副作用

波特的五力：駕馭腸漏症候群治療市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解腸漏症候群治療市場的外部影響

外部宏觀環境因素在塑造腸漏症候群治療市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解腸漏症候群治療市場的競爭格局

對腸漏症候群治療市場的詳細市場佔有率分析可以對供應商的表現進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣腸漏症候群治療市場供應商的績效評估

FPNV 定位矩陣是評估腸漏症候群治療市場供應商的關鍵工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，以確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議，為腸漏症候群治療市場的成功指明道路

對於希望加強在全球市場的影響力的公司來說，對腸漏症候群治療市場的策略分析至關重要。透過考慮關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 具有 LGS 危險因子並需要治療的人口不斷增加
      • 各國政府和國際組織對 LGS 的認知不斷提高
      • 孤兒藥認定增加
    • 抑制因素
      • LGS 診斷的限制和治療費用高
    • 機會
      • LGS 處理植物化學物質簡介
      • LGS治療的技術進步
    • 任務
      • 與現有治療相關的副作用
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章腸漏症候群治療市場（依治療類型）

  • 非手術治療
    • 靜脈注射免疫球蛋白治療
    • 生酮飲食產品
  • 外科手術

第7章腸漏症候群治療市場：依給藥途徑

  • 口服
  • 胃腸外的

第8章腸漏症候群治療市場：按分銷管道

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第 9 章腸漏症候群治療市場：依最終使用者分類

  • 居家護理
  • 醫院
  • 專科診所

第10章美洲腸漏症候群治療市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太腸漏症候群治療市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章歐洲、中東和非洲腸漏症候群治療市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Abbott Laboratories
  • Amneal Pharmaceuticals Inc.
  • Aquestive Therapeutics Inc.
  • Bausch Health Companies Inc.
  • Cision Ltd.
  • Eisai Co. Ltd.
  • GlaxoSmithKline PLC
  • GW Pharmaceuticals PLC
  • H. Lundbeck A/S
  • Johnson and Johnson
  • Lupin Ltd.
  • Marinus Pharmaceuticals Inc.
  • Pfizer Inc.
  • Sanofi SA
  • Sun Pharmaceutical Industries Ltd
  • Supernus Pharmaceuticals Inc.
  • Teva Pharmaceutical Industries Ltd.
  • UCB SA
  • Upsher Smith Laboratories LLC
  • Viatris Inc.
Product Code: MRR-742BD518076B

The Lennox-Gastaut Syndrome Treatment Market was valued at USD 643.29 million in 2023, expected to reach USD 670.63 million in 2024, and is projected to grow at a CAGR of 5.28%, to USD 922.38 million by 2030.

Lennox-Gastaut Syndrome (LGS) is a rare and severe form of epilepsy that typically manifests in early childhood and is characterized by multiple types of seizures and cognitive impairment. The scope of the market for LGS treatment includes diagnosing, managing seizures, and improving patients' quality of life. Currently, necessity in the market is driven by the high unmet medical need given the severity and resistance of LGS to treatments. Application includes antiepileptic drugs, dietary therapies, and surgical interventions, focusing on reducing seizure frequency and severity. The end-use scope primarily covers pediatric neurology departments, specialty clinics, hospitals, and home care settings.

KEY MARKET STATISTICS
Base Year [2023] USD 643.29 million
Estimated Year [2024] USD 670.63 million
Forecast Year [2030] USD 922.38 million
CAGR (%) 5.28%

The growth of the LGS treatment market is significantly influenced by increased awareness and diagnostic capabilities, leading to early detection. Additionally, ongoing clinical trials and research into new drug mechanisms, such as Cannabidiol (CBD) formulations, have presented potential opportunities for market expansion. Recommendations include leveraging advances in genetic research and personalized medicine to develop more targeted therapies. However, the market faces limitations such as high treatment costs, side effects of existing medications, and a complex regulatory landscape for new drug approvals, which challenge growth. The market is further constrained by limited understanding of LGS's underlying pathophysiology, resulting in a challenging environment for breakthrough innovations.

The best possible areas for innovation and research include exploring novel pharmacological agents with improved efficacy and safety profiles, enhancing non-pharmacological therapies like neurostimulation devices, and pushing advancements in gene therapy. Encouraging collaborative research initiatives and partnerships with academic institutions can also pave the way for pioneering treatments. The nature of the market is dynamic and niche, necessitating focus on both therapy development and comprehensive care models. Players in the industry should invest in long-term R&D and strategic alliances to create innovative solutions that address both the seizures and cognitive impairments associated with LGS.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Lennox-Gastaut Syndrome Treatment Market

The Lennox-Gastaut Syndrome Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising population with risk factors for LGS and need for treatment
    • Growing awareness of LGS by governments and global organizations
    • Rise in orphan drug designation
  • Market Restraints
    • Limitations in diagnosing LGS and high cost of treatment
  • Market Opportunities
    • Introduction of phytochemicals for LGS treatment
    • Technological advancements in the treatment of LGS
  • Market Challenges
    • Side effects associated with available treatment

Porter's Five Forces: A Strategic Tool for Navigating the Lennox-Gastaut Syndrome Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Lennox-Gastaut Syndrome Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Lennox-Gastaut Syndrome Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Lennox-Gastaut Syndrome Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Lennox-Gastaut Syndrome Treatment Market

A detailed market share analysis in the Lennox-Gastaut Syndrome Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Lennox-Gastaut Syndrome Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Lennox-Gastaut Syndrome Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Lennox-Gastaut Syndrome Treatment Market

A strategic analysis of the Lennox-Gastaut Syndrome Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Lennox-Gastaut Syndrome Treatment Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Amneal Pharmaceuticals Inc., Aquestive Therapeutics Inc., Bausch Health Companies Inc., Cision Ltd., Eisai Co. Ltd., GlaxoSmithKline PLC, GW Pharmaceuticals PLC, H. Lundbeck A/S, Johnson and Johnson, Lupin Ltd., Marinus Pharmaceuticals Inc., Pfizer Inc., Sanofi SA, Sun Pharmaceutical Industries Ltd, Supernus Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd., UCB SA, Upsher Smith Laboratories LLC, and Viatris Inc..

Market Segmentation & Coverage

This research report categorizes the Lennox-Gastaut Syndrome Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Therapy Type, market is studied across Non-Surgical Treatment and Surgery. The Non-Surgical Treatment is further studied across Intravenous Immunoglobulin Therapy and Ketogenic Diet Products.
  • Based on Route of Administration, market is studied across Oral and Parenteral.
  • Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
  • Based on End Users, market is studied across Homecare, Hospitals, and Specialty Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising population with risk factors for LGS and need for treatment
      • 5.1.1.2. Growing awareness of LGS by governments and global organizations
      • 5.1.1.3. Rise in orphan drug designation
    • 5.1.2. Restraints
      • 5.1.2.1. Limitations in diagnosing LGS and high cost of treatment
    • 5.1.3. Opportunities
      • 5.1.3.1. Introduction of phytochemicals for LGS treatment
      • 5.1.3.2. Technological advancements in the treatment of LGS
    • 5.1.4. Challenges
      • 5.1.4.1. Side effects associated with available treatment
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Lennox-Gastaut Syndrome Treatment Market, by Therapy Type

  • 6.1. Introduction
  • 6.2. Non-Surgical Treatment
    • 6.2.1. Intravenous Immunoglobulin Therapy
    • 6.2.2. Ketogenic Diet Products
  • 6.3. Surgery

7. Lennox-Gastaut Syndrome Treatment Market, by Route of Administration

  • 7.1. Introduction
  • 7.2. Oral
  • 7.3. Parenteral

8. Lennox-Gastaut Syndrome Treatment Market, by Distribution Channel

  • 8.1. Introduction
  • 8.2. Hospital Pharmacies
  • 8.3. Online Pharmacies
  • 8.4. Retail Pharmacies

9. Lennox-Gastaut Syndrome Treatment Market, by End Users

  • 9.1. Introduction
  • 9.2. Homecare
  • 9.3. Hospitals
  • 9.4. Specialty Clinics

10. Americas Lennox-Gastaut Syndrome Treatment Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Lennox-Gastaut Syndrome Treatment Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Lennox-Gastaut Syndrome Treatment Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Amneal Pharmaceuticals Inc.
  • 3. Aquestive Therapeutics Inc.
  • 4. Bausch Health Companies Inc.
  • 5. Cision Ltd.
  • 6. Eisai Co. Ltd.
  • 7. GlaxoSmithKline PLC
  • 8. GW Pharmaceuticals PLC
  • 9. H. Lundbeck A/S
  • 10. Johnson and Johnson
  • 11. Lupin Ltd.
  • 12. Marinus Pharmaceuticals Inc.
  • 13. Pfizer Inc.
  • 14. Sanofi SA
  • 15. Sun Pharmaceutical Industries Ltd
  • 16. Supernus Pharmaceuticals Inc.
  • 17. Teva Pharmaceutical Industries Ltd.
  • 18. UCB SA
  • 19. Upsher Smith Laboratories LLC
  • 20. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. LENNOX-GASTAUT SYNDROME TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY THERAPY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY THERAPY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY END USERS, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY END USERS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. LENNOX-GASTAUT SYNDROME TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. LENNOX-GASTAUT SYNDROME TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. LENNOX-GASTAUT SYNDROME TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. LENNOX-GASTAUT SYNDROME TREATMENT MARKET DYNAMICS
  • TABLE 7. GLOBAL LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY NON-SURGICAL TREATMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY INTRAVENOUS IMMUNOGLOBULIN THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY KETOGENIC DIET PRODUCTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY SURGERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY HOMECARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. BRAZIL LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 38. BRAZIL LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 39. BRAZIL LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 40. CANADA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. CANADA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 42. CANADA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 43. CANADA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 44. CANADA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 45. MEXICO LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. MEXICO LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 47. MEXICO LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 48. MEXICO LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 49. MEXICO LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 50. UNITED STATES LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. UNITED STATES LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 52. UNITED STATES LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 53. UNITED STATES LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 54. UNITED STATES LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 55. UNITED STATES LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 56. ASIA-PACIFIC LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. ASIA-PACIFIC LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 58. ASIA-PACIFIC LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 59. ASIA-PACIFIC LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 60. ASIA-PACIFIC LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 61. ASIA-PACIFIC LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 62. AUSTRALIA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. AUSTRALIA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 64. AUSTRALIA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 65. AUSTRALIA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 66. AUSTRALIA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 67. CHINA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. CHINA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 69. CHINA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 70. CHINA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 71. CHINA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 72. INDIA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. INDIA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 74. INDIA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 75. INDIA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 76. INDIA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 77. INDONESIA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. INDONESIA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 79. INDONESIA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 80. INDONESIA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 81. INDONESIA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 82. JAPAN LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. JAPAN LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 84. JAPAN LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 85. JAPAN LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 86. JAPAN LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 87. MALAYSIA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. MALAYSIA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 89. MALAYSIA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 90. MALAYSIA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 91. MALAYSIA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 92. PHILIPPINES LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. PHILIPPINES LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 94. PHILIPPINES LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 95. PHILIPPINES LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 96. PHILIPPINES LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 97. SINGAPORE LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. SINGAPORE LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 99. SINGAPORE LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 100. SINGAPORE LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 101. SINGAPORE LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 102. SOUTH KOREA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. SOUTH KOREA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 104. SOUTH KOREA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 105. SOUTH KOREA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 106. SOUTH KOREA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 107. TAIWAN LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. TAIWAN LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 109. TAIWAN LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 110. TAIWAN LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 111. TAIWAN LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 112. THAILAND LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. THAILAND LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 114. THAILAND LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 115. THAILAND LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 116. THAILAND LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 117. VIETNAM LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. VIETNAM LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 119. VIETNAM LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 120. VIETNAM LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 121. VIETNAM LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 122. EUROPE, MIDDLE EAST & AFRICA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 128. DENMARK LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. DENMARK LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 130. DENMARK LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 131. DENMARK LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 132. DENMARK LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 133. EGYPT LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. EGYPT LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 135. EGYPT LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 136. EGYPT LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 137. EGYPT LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 138. FINLAND LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. FINLAND LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 140. FINLAND LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 141. FINLAND LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 142. FINLAND LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 143. FRANCE LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. FRANCE LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 145. FRANCE LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 146. FRANCE LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 147. FRANCE LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 148. GERMANY LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. GERMANY LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 150. GERMANY LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 151. GERMANY LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 152. GERMANY LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 153. ISRAEL LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 154. ISRAEL LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 155. ISRAEL LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 156. ISRAEL LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 157. ISRAEL LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 158. ITALY LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. ITALY LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 160. ITALY LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 161. ITALY LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 162. ITALY LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 163. NETHERLANDS LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 164. NETHERLANDS LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 165. NETHERLANDS LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 166. NETHERLANDS LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 167. NETHERLANDS LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 168. NIGERIA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 169. NIGERIA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 170. NIGERIA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 171. NIGERIA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 172. NIGERIA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 173. NORWAY LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 174. NORWAY LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 175. NORWAY LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 176. NORWAY LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 177. NORWAY LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 178. POLAND LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 179. POLAND LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 180. POLAND LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 181. POLAND LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 182. POLAND LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 183. QATAR LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 184. QATAR LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 185. QATAR LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 186. QATAR LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 187. QATAR LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 188. RUSSIA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 189. RUSSIA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 190. RUSSIA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 191. RUSSIA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 192. RUSSIA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 193. SAUDI ARABIA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 194. SAUDI ARABIA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 195. SAUDI ARABIA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 196. SAUDI ARABIA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 197. SAUDI ARABIA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 198. SOUTH AFRICA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 199. SOUTH AFRICA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 200. SOUTH AFRICA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 201. SOUTH AFRICA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 202. SOUTH AFRICA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 203. SPAIN LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 204. SPAIN LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 205. SPAIN LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 206. SPAIN LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 207. SPAIN LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 208. SWEDEN LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 209. SWEDEN LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 210. SWEDEN LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 211. SWEDEN LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 212. SWEDEN LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 213. SWITZERLAND LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 214. SWITZERLAND LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 215. SWITZERLAND LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 216. SWITZERLAND LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 217. SWITZERLAND LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 218. TURKEY LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 219. TURKEY LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 220. TURKEY LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 221. TURKEY LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 222. TURKEY LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 223. UNITED ARAB EMIRATES LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 224. UNITED ARAB EMIRATES LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 225. UNITED ARAB EMIRATES LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 226. UNITED ARAB EMIRATES LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 227. UNITED ARAB EMIRATES LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 228. UNITED KINGDOM LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 229. UNITED KINGDOM LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED KINGDOM LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED KINGDOM LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED KINGDOM LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 233. LENNOX-GASTAUT SYNDROME TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 234. LENNOX-GASTAUT SYNDROME TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023